Sulfa Resistance in Mouse-Derived Pneumocystis carinii by Lane, Brian et al.
WORKSHOPS ON OPPORTUNISTIC PROTISTS 39s 
Sulfa Resistance in Mouse-Derived Pneurnocystis carinii 
BRIAN LANE,' PAUL HOSSLER,~ MARILYN BARTLETT? SHERRY QUEENER? TERRY OREILLY,~ JAMES SMITH? AND STEVEN 
MESH NICK^,. ' Depr. of Epidemiology, Univ. of Michigan, Ann Arbor, MI, 2Dept. of Pathology and Lab. Medicine, Indiana University School of Medicine, Indianapolis, IN, 
and 'Pharma Research, Ciba-Geigy. Basel, Switzerland 
Sulfa drugs, such as sulfamethoxazole and dapsone, are pivotal 
for the prophylaxis and therapy of P. curinii pneumonia. Sulfa 
drugs act by inhibiting dihydropteroate synthetase (DHPS), an 
enzyme involved in de novo folate biosynthesis. In P. carinii, 
DHPS is part of a trifunctional protein, Fas, which has previously 
been cloned and sequenced from rat-derived organisms ( I ) .  
Sulfa resistance has developed in a variety of bacterial and 
protozoan pathogens. In most cases, resistance has been shown to 
be due to point mutations in the gene coding for DHPS. In order to 
investigate whether sulfa resistance mutations could occur in P .  
carinii, the DHPS coding sequence was PCR-amplified and 
sequenced from infected mice before, during and after exposure to 
several rounds of subtherapeutic doses of sulfa. 
MATERIALS AND METHODS. Latently infected SCID mice were 
immunosuppressed as described (2). For each treatment cycle, mice 
were given trimethoprim/sulfamethoxazole (251125 mg/kg) p.0. 5 
times per week for 3 weeks. There were 4 treatment cycles. In 
between any two treatment cycles was a 3 week period without 
treatment. Mice were sacrificed before and after the experiment and 
the lungs were frozen. 
Lung homogenates were then injected intratracheally into 
immunosuppressed germ-free mice (3). These mice were given 
sulfamethoxazole (0.3 mg/kg/d) in their drinking water for 6 weeks 
and sacrificed. Lung homogenates from these mice were passaged 
one more time into immunosuppressed mice, this time administered 
sulfamethoxazole at 0.4 mg/kg/d. As a control for the latter 
passage, mice infected with the IU strain of P. curinii were also 
treated with sulfamethoxazole at 0.4 mg/kg/d. At the end of 6 
weeks, both sets of mice were sacrificed and the degree of infection 
scored. 
DNA was extracted from frozen lungs and PCR-amplified as 
previously described (4). Amplifed products were gel-purified and 
sequenced by dye-terminator automated sequencing. 
RESULTS AND DISCUSSION. In order to ascertain whether the 
drug-treated organisms were resistant to sulfa, lungs were removed 
from treated and untreated mice and assessed for degree of infection 
(Table 1) (5). While mice infected with the IU strain demonstrated 
marked decreases in organism burden after treatment with 
sulfamethoxazole (0.8 vs 4.1), mice infected with the P. carinii 
strainexposed to sulfa showed very poor responses to sulfa 
treatment (2.2 vs 3.5). These data suggest that the treated 
organisms had developed resistance to sulfa. 
Table 1. Effects of sulfamethoxazole on degree of infection in 
P. carinii strain Treated Untreated 
Drug-exposed 2.2 k 0.24 3.5 f 0.14 
IU strain 0.8 f 0.24 4.1 f 0.09 
(Giemsa score) 
DHPS sequences were obtained from infected lungs before 
treatment, after initial treatment, after the first passage mice were 
sacrificed and after the second passage mice were sacrificed. All 
four sequences were 100% identical at the nucleotide level. The 
deduced amino acid sequence is shown in Figure 1 and is 94% 
idetnical to the sequence from rat-derived P. carinii. The DHPS 
nucleotide sequence from the treated strain, which was originally 
derived in Ciba-Geigy in Switzerland, was 100% identical to the 
DHPS nucleotide sequence from the IU strain (4) which has been 
maintained at Indiana University. 
Continuous exposure of P. carinii-infected mice to 
subtherapeutic levels of sulfa appears to have led to the 
development of sulfa resistance. The resistance, however, was not 
due to a mutation within the coding sequence of DHPS. Thus, 
another mechanism of drug resistance appears to be responsible for 
the observed phenotype. Other possible mechanisms, including 
impaired drug accumulation, gene amplification and mutations on 
other positions in the Fas gene are now under investigation. 
The relative stability of the DHPS in mouse-derived P. carinii 
contrasts starkly with recent evidence for polymorphisms within 
the DHPS from human-derived organisms (4). [Supported by NIH 
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Figure 1. Deduced amino acid sequence of P. carinii DHPS from untreated SCID mice and after exposure to sulfamethoxazole. Second line 
represents alignment with the DHPS from rat-derived P. carinii ( l ) ,  showing only amino acid differences. 
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